INTRODUCTION {#sec1-1}
============

Diabetes mellitus is a heterogenous group of metabolic disorders characterized by chronic hyperglycemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in either insulin secretion, insulin action or both.\[[@ref1]\]

The world wide prevalence of diabetes mellitus has risen dramatically over the two decades, from an estimated million cases in 1985 to 177 million in 2000. Based on current trends, more than 360 million individuals will have diabetes by the year 2030.\[[@ref2]\] Type 2 diabetes is rising much more rapidly because of increasing obesity and reduced activity.

Criteria for the diagnosis of diabetes mellitus.\[[@ref3]\]

Symptoms of diabetes plus random blood glucose concentration ≥ 11.1 mM (200 mg/dL) orFasting plasma glucose ≥ 7.0 mM (126 mg/dL) orTwo-hour plasma glucose ≥ 11.1 mM(200 mg/dL) during an oral glucose tolerance test.Hb A~1c~ ≥ 6.5%.

The disease states underlying the diagnosis of diabetes mellitus are now classified in to four categories: Type 1, Insulin dependent diabetes; Type 2, Non-insulin dependent diabetes; Type 3, Other specific types; Type 4, Gestational diabetes mellitus (Expert committee, 2003).\[[@ref4]\]

Type 2 diabetes is characterized by impaired insulin secretion, insulin resistance, excessive hepatic glucose production and abnormal fat metabolism.\[[@ref2]\]

Insulin is the mainstay for the treatment of virtually all Type 1 diabetes mellitus and many Type 2 diabetes mellitus.\[[@ref5]\] Type 2 diabetes mellitus can be managed by diet, exercise, oral anti-diabetic agents and insulin in certain conditions.

Oral anti-diabetic agents consist of insulin secretogogues-sulfanylureas 1^st^ and 2^nd^ generations, meglitinides, biguanides, thiozolidinediones, a-glucosidase inhibitors, incretin-based therapies, and amylin analogs.\[[@ref4]\]

Thiozolidinediones were introduced in 1997 as the insulin sensitisers.\[[@ref5]\] The first of these agents, troglitazone was associated with the rare development of idiosyncratic liver toxicity, which could progress to hepatic failure and death, and troglitazone was withdrawn from the market in March 2000.\[[@ref6]\] Patients using rosiglitazone have experienced a number of serious side effects including cardiovascular events and adverse effects on lipid profile leading to its ban in India in 2010.\[[@ref7]\]

In thiozolidinediones group, pioglitazone is more widely used drug. Hence, the present study was undertaken to assess the acute toxicity of pioglitazone which can also occur in the accidental overdose where a very few reports are available of pioglitazone acute toxicity.

MATERIALS AND METHODS {#sec1-2}
=====================

Materials {#sec2-1}
---------

### Animals {#sec3-1}

Swiss albino mice for the study were obtained from the animal house of our institute. The study was approved by the institutional animal ethics committee of the institute and the experiments were carried out as per the guidelines of Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA).

### Pioglitazone {#sec3-2}

Pioglitazone, C~19~H~20~N~2~O~3~S, has a molecular weight of 392.90. Pioglitazone (Pioz, Usv Limited, Mumbai, India) was procured from the market, dissolved in distilled water and administered to the mice. Its LD~50~ is 2000 mg/kg in mice, given orally.

Methods {#sec2-2}
-------

Swiss albino mice of either sex weighing between 20 and 35 g were selected for the experiment. A total of 18 mice were taken and divided into 3 groups of 6 each as Control, Test ¼ LD~50~ and Test ½ LD~50~. The mice in groups were marked and kept for overnight fasting in separate labeled cages. On the following day, the mice were administered as scheduled below.\[[@ref8]\]

Group I (contol) - 0.5 ml distilled water, single dose.

Group II (¼ LD~50~) - 500 mg/kg pioglitazone, single dose.

Group III (½ LD~50~) - 1000 mg/kg pioglitazone, single dose.

All the animals had free access to food and water after drug administration. After 24 hrs, they were sacrificed by cervical dislocation. Heart, liver and kidneys were dissected and subjected to histopathological examination.

RESULTS {#sec1-3}
=======

Group I (control) Treated with 0.5 ml distilled water, single dose, oral.

In this group, the histopathological examination of heart, liver and kidneys revealed no changes \[[Table 1](#T1){ref-type="table"} and Figures [1](#F1){ref-type="fig"}--[3](#F3){ref-type="fig"}\].

###### 

Group I (control). Treated with 0.5 ml distilled water, single dose, oral

![](TI-19-250-g001)

![Group I(Conrol) Heart-Normal](TI-19-250-g002){#F1}

![Gorup I Liver-Normal](TI-19-250-g003){#F2}

![Group I (Control) Kidney-Normal](TI-19-250-g004){#F3}

Group II (¼ LD~50~) Treated with 500 mg/kg of pioglitazone, single dose, oral.

There was ventricular hypertrophy of heart in 4 out of 6 mice \[[Table 2](#T2){ref-type="table"} and [Figure 4](#F4){ref-type="fig"}\]. Liver histopathological studies have shown mild congestion in 4 out of 6 mice \[[Table 2](#T2){ref-type="table"} and [Figure 5](#F5){ref-type="fig"}\]. Mild congestion of kidneys was seen in 2 out of 6 mice \[[Table 2](#T2){ref-type="table"} and [Figure 6](#F6){ref-type="fig"}\].

###### 

Group II (¼ LD~50~). Treated with 500 mg/kg of pioglitazone, single dose, oral

![](TI-19-250-g005)

![Group II(1/4 LD50) Heart-Ventricular Hypertrophy](TI-19-250-g006){#F4}

![Group II (1/4 LD50)Liver-Mild congestion](TI-19-250-g007){#F5}

![Group II (1/4 LD50) Kidney-Mild congestion](TI-19-250-g008){#F6}

Group III (½ LD~50~) Treated with 1000 mg/kg of pioglitazone, single dose, oral.

Two mice out of 6 have died within 24 hours of pioglitazone administration.

The histopathological studies of remaining 4 mice have shown ventricular hypertrophy of heart and congestion of liver and kidneys \[[Table 3](#T3){ref-type="table"} and Figures [7](#F7){ref-type="fig"}--[9](#F9){ref-type="fig"}\].

###### 

Group III (½ LD~50~). Treated with 1000 mg/kg pioglitazone, single dose, oral

![](TI-19-250-g009)

![Group III(1/2 LD50) Heart-Ventricular Hypertrophy](TI-19-250-g010){#F7}

![Group III (1/2 LD50) Liver-congestion](TI-19-250-g011){#F8}

![Group III (1/2 LD50) Kidney-congestion](TI-19-250-g012){#F9}

DISCUSSION {#sec1-4}
==========

The study was done to assess the acute toxicity of pioglitazone in mice. Pioglitazone, a thiazolidinedione, is a selective agonist of nuclear peroxisome proliferator activated receptor γ (PPAR-γ). This nuclear receptor regulates the transcription of genes encoding proteins involved in carbohydrate and lipid metabolism. It increases glucose uptake in muscles and adipose tissue. It also increases GLUT~4~ and decreases hepatic gluconeogenesis and reduces blood glucose level.

Pioglitazone enhances insulin action on liver, adipose tissue and skeletal muscles and confer improvement in glycemic control in persons with type 2 diabetes. It is approved as a monotherapy and in combination with metformin, sulfonylureas, and insulin for the treatment of type 2 diabetes.

It is a well known fact that type 2 diabetes has an increased risk of all the manifestations of atherosclerotic vascular disease. The adverse effect of pioglitazone is edema, weight gain, reduction in hematocrit and worsening of congestive heart failure, macular edema, usually occur in association with more general fluid retention.\[[@ref9]\] There is also an increase in the risk of bone fractures in women.\[[@ref4]\]

Recent evidence suggests that rosiglitazone, but not pioglitazone, increases the risk of cardiovascular events (myocardial infarction, stroke). But in post marketing experience with pioglitazone, cases of congestive heart failure have been reported in patients both with and without previously suffering from heart disease.\[[@ref10]\]

In the experiment done in mice, acute administration of large doses ¼ LD~50~ and ½ LD~50~ of pioglitazone resulted in ventricular hypertrophy with congestion in liver and kidneys which can also happen with accidental overdose of pioglitazone in patients. It is therefore advisable not to prescribe pioglitazone in diabetic patients associated with congestive heart failure as well as chronic hypertension, as chronic hypertension leads to ventricular hypertrophy which might worsen due to chronic administration of pioglitazone. Further study has to be done as how to reduce ventricular hypertrophy.
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